Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Rosacea
Interventions
DRUG

Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel

Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks

DRUG

Placebo gel

Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks

Trial Locations (2)

94305

Department of Dermatology - Stanford School of Medicine, Stanford

02114

CURTIS - Massachussetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Medicis Pharmaceutical Corporation

INDUSTRY

lead

Massachusetts General Hospital

OTHER